CANNAINVESTOR Magazine February / March 2017 - Page 22

PRE-CLINICAL RESEARCH: BRAIN CANCER

Highlights

•Partnering with one of Australia’s leading medical research institutes, the Telethon Kids Institute

•We have expanded pre-clinical research program from breast cancer to now include pediatric brain cancers

•Developing a rigorous series of experiments to generate high quality data pack

•Data expected during 2017

Zelda Therapeutics Ltd is working with the highly regarded, Perth-based Telethon Kids Institute (www.telethonkids.org.au). This collaboration will initially focus on pre-clinical testing of Zelda’s compounds, formulations and protocols in the area of children’s brain cancer.

The collaboration with the Telethon Kids Institute will be confined to pre-clinical research accessing the Institute’s validated cell and animal models for the studies. Through the research, the Institute will examine the potential for Zelda’s compounds to act as anti-cancer agents, either alone or in combination with existing treatments. The initial studies commence in early 2017 with results expected later in the year.

"The new collaboration with the Telethon Kids Institute demonstrates the Company’s strong momentum towards conducting rigorous pre-clinical and clinical studies aimed at validating the anecdotal patient responses to medical cannabis observed to date, to produce industry- standard data packs and trial data." - Harry Karelis, Executive Chairman

The research consists of a series of experiments that have been designed within stringent scientific protocols to produce a comprehensive data pack that can be used as the basis for any future clinical trials either in Australia or in other geographies.

The collaboration and studies, build on the Company’s pre-clinical research activities at Complutense University Madrid with renowned researchers Professor Manuel Guzmán and Professor Cristina Sánchez who are both considered the leaders in the research of anti-cancer effects of cannabinoids.

22